Viaskin Peanut 250 mcg

Phase 2Completed
0 watching 0 views this week Active
47
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peanut Allergy

Conditions

Peanut Allergy

Trial Timeline

Sep 1, 2013 → Sep 1, 2016

About Viaskin Peanut 250 mcg

Viaskin Peanut 250 mcg is a phase 2 stage product being developed by DBV Technologies for Peanut Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT01955109. Target conditions include Peanut Allergy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01955109Phase 2Completed